| Male gender | 1.248 | 0.017 |
| JIA category other than systemic arthritis | 1.541 | 0.024 |
| Shorter disease duration before start of therapy | 1.230 | 0.019 |
| No therapy with chloroquine before therapy | 1.580 | 0.045 |
| No therapy with MTX before therapy with ETA | 1.254 | 0.011 |
| Lower clinician global assessment of disease activity VAS at start of therapy (SOT)* | 1.004* | 0.026 |
| Therapy MTX compared to ETA | 1.0003 | 0.021 |
| Combination therapy separate: |
| MTX/ETA mono | 1.195 | 0.208 |
| MTX/ETA+MTX | 1.235 | 0.026 |
| Lower patient global assessment of overall well-being VAS at end |
| of therapy (EOT) | 1.006* | 0.043 |